Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Residence Characteristics | 13 | 2025 | 268 | 3.490 |
Why?
|
| Socioeconomic Factors | 11 | 2025 | 865 | 2.010 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2024 | 938 | 1.840 |
Why?
|
| Liver Neoplasms | 4 | 2024 | 1312 | 1.660 |
Why?
|
| Texas | 22 | 2024 | 3558 | 1.330 |
Why?
|
| Cyclonic Storms | 4 | 2023 | 75 | 1.250 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2024 | 237 | 1.080 |
Why?
|
| Transportation | 2 | 2019 | 26 | 1.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 805 | 0.980 |
Why?
|
| Walking | 4 | 2019 | 210 | 0.860 |
Why?
|
| Schools | 5 | 2025 | 221 | 0.860 |
Why?
|
| Registries | 7 | 2024 | 1398 | 0.850 |
Why?
|
| Environment Design | 4 | 2019 | 14 | 0.850 |
Why?
|
| Health Status Disparities | 4 | 2024 | 221 | 0.840 |
Why?
|
| Floods | 3 | 2022 | 14 | 0.830 |
Why?
|
| Arsenic | 1 | 2023 | 46 | 0.810 |
Why?
|
| Social Class | 3 | 2025 | 190 | 0.740 |
Why?
|
| Pediatric Obesity | 5 | 2017 | 384 | 0.680 |
Why?
|
| Disasters | 1 | 2021 | 98 | 0.660 |
Why?
|
| Public Facilities | 1 | 2019 | 2 | 0.650 |
Why?
|
| Bicycling | 1 | 2019 | 39 | 0.630 |
Why?
|
| Hypersensitivity | 1 | 2021 | 182 | 0.620 |
Why?
|
| Incidence | 8 | 2024 | 3055 | 0.610 |
Why?
|
| Geographic Information Systems | 2 | 2015 | 40 | 0.590 |
Why?
|
| Overweight | 1 | 2020 | 358 | 0.580 |
Why?
|
| Stress, Psychological | 2 | 2021 | 555 | 0.570 |
Why?
|
| Pandemics | 5 | 2023 | 1100 | 0.540 |
Why?
|
| Mexican Americans | 2 | 2015 | 204 | 0.520 |
Why?
|
| Exercise | 2 | 2019 | 814 | 0.500 |
Why?
|
| Communicable Disease Control | 5 | 2023 | 138 | 0.460 |
Why?
|
| Safety | 2 | 2016 | 218 | 0.460 |
Why?
|
| Humans | 49 | 2025 | 123280 | 0.440 |
Why?
|
| Male | 39 | 2025 | 60345 | 0.420 |
Why?
|
| Female | 34 | 2025 | 65628 | 0.420 |
Why?
|
| Spatial Analysis | 2 | 2024 | 21 | 0.420 |
Why?
|
| Health Behavior | 4 | 2020 | 382 | 0.410 |
Why?
|
| Adult | 17 | 2024 | 29091 | 0.390 |
Why?
|
| Fenfluramine | 3 | 1997 | 11 | 0.370 |
Why?
|
| Motor Activity | 2 | 2014 | 522 | 0.360 |
Why?
|
| Parents | 2 | 2016 | 1032 | 0.360 |
Why?
|
| Environmental Exposure | 2 | 2024 | 218 | 0.350 |
Why?
|
| Middle Aged | 12 | 2024 | 26095 | 0.320 |
Why?
|
| Analgesics | 4 | 1994 | 134 | 0.310 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 3384 | 0.300 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 532 | 0.290 |
Why?
|
| United States | 13 | 2025 | 10655 | 0.270 |
Why?
|
| Child | 15 | 2025 | 24262 | 0.270 |
Why?
|
| Aged | 8 | 2024 | 19180 | 0.260 |
Why?
|
| Surveys and Questionnaires | 9 | 2022 | 3678 | 0.260 |
Why?
|
| Child, Preschool | 8 | 2024 | 13927 | 0.250 |
Why?
|
| Research Design | 5 | 2020 | 679 | 0.250 |
Why?
|
| Social Environment | 2 | 2016 | 119 | 0.240 |
Why?
|
| Sex Characteristics | 3 | 2023 | 317 | 0.240 |
Why?
|
| Young Adult | 7 | 2024 | 8870 | 0.240 |
Why?
|
| Adolescent | 12 | 2025 | 19126 | 0.240 |
Why?
|
| Culex | 1 | 2024 | 31 | 0.240 |
Why?
|
| Mosquito Vectors | 1 | 2024 | 33 | 0.230 |
Why?
|
| Geography, Medical | 1 | 2023 | 16 | 0.220 |
Why?
|
| Papillomavirus Vaccines | 1 | 2024 | 93 | 0.210 |
Why?
|
| Serotonin | 2 | 1994 | 232 | 0.210 |
Why?
|
| Wounds, Gunshot | 1 | 2024 | 139 | 0.200 |
Why?
|
| Hypothalamus | 2 | 1994 | 217 | 0.200 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 146 | 0.200 |
Why?
|
| Endocrine Disruptors | 1 | 2022 | 53 | 0.200 |
Why?
|
| Pain | 4 | 2022 | 470 | 0.200 |
Why?
|
| Peritoneal Dialysis | 1 | 2023 | 118 | 0.190 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2022 | 67 | 0.190 |
Why?
|
| Arginine Vasopressin | 2 | 1992 | 28 | 0.190 |
Why?
|
| Sociological Factors | 1 | 2021 | 8 | 0.180 |
Why?
|
| Workplace Violence | 1 | 2020 | 3 | 0.180 |
Why?
|
| Social Isolation | 1 | 2020 | 41 | 0.180 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 284 | 0.180 |
Why?
|
| Program Evaluation | 3 | 2023 | 448 | 0.180 |
Why?
|
| Rectal Neoplasms | 1 | 2021 | 78 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 479 | 0.170 |
Why?
|
| Public Opinion | 1 | 2020 | 56 | 0.170 |
Why?
|
| House Calls | 1 | 2020 | 37 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 174 | 0.170 |
Why?
|
| Receptors, Serotonin | 2 | 1997 | 42 | 0.170 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 160 | 0.160 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1803 | 0.160 |
Why?
|
| Cities | 1 | 2019 | 48 | 0.160 |
Why?
|
| Stress, Physiological | 2 | 1991 | 258 | 0.160 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 197 | 0.160 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 247 | 0.160 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2019 | 137 | 0.150 |
Why?
|
| Outpatients | 1 | 2020 | 254 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2021 | 373 | 0.150 |
Why?
|
| Health Services Accessibility | 2 | 2023 | 595 | 0.150 |
Why?
|
| Educational Status | 2 | 2021 | 270 | 0.150 |
Why?
|
| Health Status | 1 | 2020 | 375 | 0.150 |
Why?
|
| Survivors | 1 | 2020 | 344 | 0.150 |
Why?
|
| Social Media | 1 | 2020 | 108 | 0.150 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 120 | 0.150 |
Why?
|
| Students | 2 | 2025 | 254 | 0.150 |
Why?
|
| Mental Health | 1 | 2020 | 345 | 0.140 |
Why?
|
| 5-Hydroxytryptophan | 1 | 1997 | 3 | 0.140 |
Why?
|
| Community Networks | 1 | 2017 | 33 | 0.140 |
Why?
|
| Eating | 2 | 1997 | 373 | 0.140 |
Why?
|
| Interleukin-1 | 2 | 1995 | 143 | 0.140 |
Why?
|
| Thiazepines | 1 | 1997 | 8 | 0.140 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1997 | 26 | 0.140 |
Why?
|
| Appetite Depressants | 1 | 1997 | 22 | 0.140 |
Why?
|
| Behavior, Animal | 3 | 1997 | 477 | 0.140 |
Why?
|
| Fluoxetine | 1 | 1997 | 43 | 0.140 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 442 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2023 | 844 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 392 | 0.130 |
Why?
|
| Attitude to Health | 2 | 2015 | 260 | 0.130 |
Why?
|
| Hypertension | 1 | 2025 | 1284 | 0.130 |
Why?
|
| Mice, Inbred Strains | 6 | 1995 | 312 | 0.130 |
Why?
|
| Neoplasms | 3 | 2024 | 2759 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 561 | 0.120 |
Why?
|
| Prednisolone | 1 | 1995 | 72 | 0.120 |
Why?
|
| Indomethacin | 1 | 1995 | 84 | 0.120 |
Why?
|
| Survival Rate | 1 | 2020 | 2005 | 0.120 |
Why?
|
| Retrospective Studies | 6 | 2023 | 16081 | 0.120 |
Why?
|
| Norfenfluramine | 1 | 1994 | 1 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 417 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 357 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
|
| Family Relations | 1 | 2015 | 68 | 0.120 |
Why?
|
| Naloxone | 2 | 1991 | 46 | 0.110 |
Why?
|
| School Health Services | 1 | 2015 | 101 | 0.110 |
Why?
|
| Physical Fitness | 1 | 2014 | 91 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 5061 | 0.110 |
Why?
|
| Feeding and Eating Disorders | 1 | 1994 | 70 | 0.110 |
Why?
|
| Physicians | 1 | 2020 | 581 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2015 | 165 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2015 | 212 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1995 | 303 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1995 | 280 | 0.100 |
Why?
|
| Receptors, Vasopressin | 1 | 1992 | 11 | 0.100 |
Why?
|
| Body Temperature Regulation | 1 | 1992 | 32 | 0.100 |
Why?
|
| Asthma | 1 | 2020 | 744 | 0.100 |
Why?
|
| Dopamine | 1 | 1994 | 284 | 0.100 |
Why?
|
| Codeine | 1 | 1992 | 24 | 0.100 |
Why?
|
| Morphine | 1 | 1992 | 88 | 0.100 |
Why?
|
| Behavioral Medicine | 1 | 2011 | 11 | 0.100 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 1992 | 121 | 0.090 |
Why?
|
| Models, Educational | 1 | 2011 | 71 | 0.090 |
Why?
|
| Histamine | 1 | 1991 | 44 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1990 | 8 | 0.090 |
Why?
|
| Primary Health Care | 1 | 2017 | 754 | 0.090 |
Why?
|
| Prognosis | 1 | 2020 | 4518 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1316 | 0.090 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1990 | 47 | 0.090 |
Why?
|
| Research Personnel | 1 | 2011 | 117 | 0.090 |
Why?
|
| Analgesia | 1 | 1990 | 44 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 1994 | 747 | 0.090 |
Why?
|
| Nociceptors | 1 | 1990 | 14 | 0.090 |
Why?
|
| Injections, Intraventricular | 4 | 1992 | 65 | 0.080 |
Why?
|
| Animals | 12 | 2024 | 33850 | 0.080 |
Why?
|
| Feeding Behavior | 1 | 1994 | 707 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2014 | 1550 | 0.080 |
Why?
|
| Inflammation | 1 | 1995 | 1404 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 3 | 1997 | 1218 | 0.070 |
Why?
|
| Brain | 2 | 1997 | 2964 | 0.070 |
Why?
|
| Pain Measurement | 3 | 1994 | 358 | 0.070 |
Why?
|
| Linear Models | 2 | 2021 | 669 | 0.070 |
Why?
|
| Sex Factors | 2 | 2021 | 1262 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2011 | 517 | 0.060 |
Why?
|
| Population Density | 1 | 2024 | 33 | 0.060 |
Why?
|
| Oil and Gas Fields | 1 | 2024 | 9 | 0.060 |
Why?
|
| Rats | 3 | 1997 | 3668 | 0.060 |
Why?
|
| Risk Factors | 3 | 2025 | 10033 | 0.060 |
Why?
|
| Mice | 8 | 1995 | 17555 | 0.060 |
Why?
|
| Community-Institutional Relations | 1 | 2023 | 29 | 0.060 |
Why?
|
| Environmental Health | 1 | 2023 | 10 | 0.060 |
Why?
|
| Age Factors | 2 | 2021 | 2808 | 0.050 |
Why?
|
| Firearms | 1 | 2024 | 41 | 0.050 |
Why?
|
| Sarcoma, Ewing | 1 | 2024 | 117 | 0.050 |
Why?
|
| West Nile Fever | 1 | 2024 | 139 | 0.050 |
Why?
|
| Focus Groups | 1 | 2023 | 201 | 0.050 |
Why?
|
| Feedback | 1 | 2023 | 162 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 2 | 1994 | 73 | 0.050 |
Why?
|
| Silicones | 1 | 2022 | 33 | 0.050 |
Why?
|
| Travel | 1 | 2023 | 116 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2022 | 77 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2022 | 73 | 0.050 |
Why?
|
| Poverty Areas | 1 | 2021 | 32 | 0.050 |
Why?
|
| Hepatoblastoma | 1 | 2024 | 179 | 0.050 |
Why?
|
| Marital Status | 1 | 2021 | 34 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2023 | 186 | 0.050 |
Why?
|
| Physical Exertion | 2 | 1991 | 81 | 0.050 |
Why?
|
| Logistic Models | 2 | 2016 | 1799 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 140 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 361 | 0.040 |
Why?
|
| Hot Temperature | 2 | 1991 | 136 | 0.040 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2020 | 21 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 69 | 0.040 |
Why?
|
| Fever | 1 | 2022 | 296 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 349 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2020 | 196 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1994 | 1690 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 110 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1304 | 0.040 |
Why?
|
| Vaccination | 1 | 2024 | 947 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 172 | 0.040 |
Why?
|
| Self Report | 1 | 2022 | 517 | 0.040 |
Why?
|
| Infant | 2 | 2024 | 12370 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 241 | 0.040 |
Why?
|
| Self-Management | 1 | 2020 | 96 | 0.040 |
Why?
|
| Life Style | 1 | 2021 | 406 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 2409 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2020 | 229 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 260 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 223 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1231 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 605 | 0.030 |
Why?
|
| Serotonin Agents | 1 | 1997 | 14 | 0.030 |
Why?
|
| Neuropeptide Y | 1 | 1997 | 36 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 1997 | 103 | 0.030 |
Why?
|
| Dopamine Agonists | 1 | 1997 | 79 | 0.030 |
Why?
|
| Zymosan | 1 | 1995 | 4 | 0.030 |
Why?
|
| Exudates and Transudates | 1 | 1995 | 22 | 0.030 |
Why?
|
| Peroxidase | 1 | 1995 | 62 | 0.030 |
Why?
|
| Formaldehyde | 2 | 1992 | 31 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 827 | 0.030 |
Why?
|
| Dinoprostone | 1 | 1995 | 76 | 0.030 |
Why?
|
| Granuloma | 1 | 1995 | 68 | 0.030 |
Why?
|
| Fenclonine | 1 | 1994 | 1 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1497 | 0.030 |
Why?
|
| Microdialysis | 1 | 1994 | 56 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2015 | 78 | 0.030 |
Why?
|
| Administration, Oral | 2 | 1994 | 671 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2015 | 49 | 0.030 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1994 | 9 | 0.030 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1994 | 28 | 0.030 |
Why?
|
| Food Deprivation | 1 | 1994 | 31 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 1994 | 136 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 1994 | 186 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 1994 | 158 | 0.030 |
Why?
|
| Abdomen | 1 | 1994 | 129 | 0.030 |
Why?
|
| Data Collection | 1 | 2015 | 383 | 0.030 |
Why?
|
| Oxymorphone | 1 | 1992 | 1 | 0.030 |
Why?
|
| Body Weight | 1 | 1997 | 1007 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 667 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1078 | 0.020 |
Why?
|
| Receptors, Histamine | 1 | 1991 | 3 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 1991 | 17 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 2861 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1991 | 40 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 1992 | 104 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2014 | 323 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 4692 | 0.020 |
Why?
|
| Health Promotion | 1 | 2015 | 390 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8116 | 0.020 |
Why?
|
| Parenting | 1 | 2015 | 330 | 0.020 |
Why?
|
| Swimming | 1 | 1990 | 21 | 0.020 |
Why?
|
| Models, Psychological | 1 | 2011 | 138 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2011 | 201 | 0.020 |
Why?
|
| Norepinephrine | 1 | 1990 | 174 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1934 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1990 | 253 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 2696 | 0.020 |
Why?
|
| Cognition | 1 | 2014 | 736 | 0.020 |
Why?
|
| Reaction Time | 1 | 1990 | 170 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 3868 | 0.020 |
Why?
|
| Anxiety | 1 | 2015 | 957 | 0.020 |
Why?
|
| Arginine | 1 | 1991 | 331 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1992 | 2019 | 0.020 |
Why?
|
| HIV Infections | 1 | 2019 | 1860 | 0.020 |
Why?
|
| Diet | 1 | 1994 | 1133 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 6390 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1991 | 59 | 0.010 |
Why?
|
| Brain Chemistry | 1 | 1991 | 122 | 0.010 |
Why?
|
| Edema | 1 | 1991 | 136 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 1991 | 448 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1991 | 1327 | 0.000 |
Why?
|